Non-viral cancer gene therapy - What is best?

Drug Discovery Today

Volumn 8, Issue 2, 2003, Pages 63-

  Ogris, Manfred ^a  

^a Center of Drug Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PLASMID DNA; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BACTERIUM; CANCER; CANCER CHEMOTHERAPY; CODON USAGE; DEFENSE MECHANISM; GENE THERAPY; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONVIRAL GENE THERAPY; SHORT SURVEY;

EID: 0037439314     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02566-7     Document Type: Note

References (3)

1. Spack E.G., Sorgi F.L. The double-edged cytokine sword of non-viral gene targeting to tumors. Drug Discov. Today. 7:2002;754-755.
2. Yasuda K., et al. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem. Biophys. Res. Commun. 293:2002;344-348.
3. Kircheis R., et al. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther. 9:2002;673-680.